Progress and challenges in screening for early detection of ovarian cancer

Molecular and Cellular Proteomics

Volumn 3, Issue 4, 2004, Pages 355-366

  Jacobs, Ian J ^a   Menon, Usha ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 72-4 ANTIGEN; COLONY STIMULATING FACTOR 1; INHIBIN; KALLIKREIN; LYSOPHOSPHATIDIC ACID; MONOCLONAL ANTIBODY; OSTEOPONTIN; PROTEOME; SERINE PROTEINASE;

BLOOD BANK; CANCER MORTALITY; CANCER PATIENT; CANCER RESEARCH; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GYNECOLOGIC CANCER; HIGH RISK POPULATION; HUMAN; IMAGE PROCESSING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL ASSESSMENT; MEDICAL DOCUMENTATION; METHODOLOGY; OUTCOMES RESEARCH; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; REPRODUCIBILITY; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYMPTOM; TECHNOLOGY; TIME; TRANSVAGINAL ECHOGRAPHY; UNITED KINGDOM;

CLINICAL TRIALS; FEMALE; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTEOME; TUMOR MARKERS, BIOLOGICAL;

EID: 2542609900     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.R400006-MCP200     Document Type: Review

References (108)

1. Menon, U., and Jacobs, I. J. (2002) The current status of screening for ovarian cancer. In Ovarian Cancer (Jacobs, I. J., Shepherd, J. H., Oram, D. H., Blackett, A. D., Luesley, D. M., Berchuck, A., and Hudson, C. N., eds) pp. 171-178, Oxford University Press, London
2. Wilson, J., and Jungner, G. (1968) WHO principles and practice of screening for disease. WHO 66-67
3. Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., Loman, N., Olsson, H., Johannsson, O., Borg, A., et al. (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130
4. Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J., Lynch, P., McTiernan, A., Offit, K., Perlman, J., Petersen, G., Thomson, E., and Varricchio, C. (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. J. Am. Med. Assoc. 277, 997-1003
5. Tamakoshi, K., Kikkawa, F., Shibata, K., Tomoda, K., Obata, N. H., Wakahara, F., Tokuhashi, Y., Ishikawa, H., Kawai, M., and Tomoda, Y. (1996) Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol. Oncol. 62, 67-72
6. Negishi, Y., Iwabuchi, H., Sakunaga, H., Sakamoto, M., Okabe, K., Sato, H., and Asano, G. (1993) Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol. Oncol. 48, 148-154
7. Jacobs, I. J., Rivera, H., Oram, D. H., and Bast, R. C., Jr. (1993) Differential diagnosis of ovarian cancer with tumour markers CA 125, CA15-3 and TAG 72,3. Br. J. Obstet. Gynaecol. 100, 1120-1124
8. Xu, F. J., Ramakrishnan, S., Daly, L., Soper, J. T., Berchuck, A., Clarke-Pearson, D., and Bast, R. C., Jr. (1991) Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am. J. Obstet. Gynecol. 165, 1356-1362
9. Woolas, R. P., Xu, F. J., Jacobs, I. J., Yu, Y. H., Daly, L., Berchuck, A., Soper, J. T., Clarke-Pearson, D. L., Oram, D. H., and Bast, R. C., Jr. (1993) Elevation of multiple serum markers in patients with stage I ovarian cancer. J. Natl. Cancer Inst. 85, 1748-1751
10. Xu, F. J., Yu, Y. H., Li, B. Y., Moradi, M., Elg, S., Lane, C., Carson, L., and Ramakrishnan, S. (1991) Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res. 51, 4012-4019
11. Hogdall, E. V., Hogdall, C. K., Kjaer, S. K., Xu, F., Yu, Y., Bast, R. C., Blaakaer, J., and Jacobs, I. J. (1999) OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin. Chem. 45, 692-694
12. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J. Am. Med. Assoc. 280, 719-723
13. Mok, S. C., Chao, J., Skates, S., Wong, K., Yiu, G. K., Muto, M. G., Berkowitz, R. S., and Cramer, D. W. (2001) Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology, J. Natl. Cancer Inst. 93, 1458-1464
14. Kim, J. H., Skates, S. J., Uede, T., Wong, K. K., Schorge, J. O., Feltmate, C. M., Berkowitz, R. S., Cramer, D. W., and Mok, S. C. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. J. Am. Med. Assoc. 287, 1671-1679
15. Robertson, D. M., Stephenson, T., Pruysers, E., Burger, H. G., McCloud, P., Tsigos, A., Groome, N., Mamers, P., McNeilage, J., Jobling, T., and Healy, D. (2002) Inhibins/activins as diagnostic markers for ovarian cancer. Mol. Cell. Endocrinol. 191, 97-103
16. Diamandis, E. P., Yousef, G. M., Soosaipillai, A. R., and Bunting, P. (2000) Human kallikrein 6 (zyme/protease M/neurosin): A new serum biomarker of ovarian carcinoma. Clin. Biochem. 33, 579-583
17. Yousef, G. M., and Diamandis, E. P. (2002) Expanded human tissue kallikrein family - A novel panel of cancer biomarkers. Tumour Biol. 23, 185-192
18. Shvartsman, H. S., Lu, K. H., Lee, J., Lillie, J., Deavers, M. T., Clifford, S., Wolf, J. K., Mills, G. B., Bast, R. C., Jr., Gershenson, D. M., and Schmandt, R. (2003) Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol. 90, 44-50
19. Kabawat, S. E., Bast, R. C., Jr., Bhan, A. K., Welch, W. R., Knapp, R. C., and Colvin, R. B. (1983) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int. J. Gynecol. Pathol. 2, 275-285
20. Nap, M. (1998) Immunohistochemistry of CA 125. Unusual expression in normal tissues, distribution in the human fetus and questions around its application in diagnostic pathology. Int. J. Biol. Markers 13, 210-215
21. Bast, R. C., Jr., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., and Knapp, R. C. (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337
22. Nustad, K., Bast, R. C., Jr., Brien, T. J., Nilsson, O., Seguin, P., Suresh, M. R., Saga, T., Nozawa, S., Bormer, O. P., de Bruijn, H. W., et al. (1996) Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: First report from the ISOBM TD-1 workshop, International Society for Oncodevelopmental Biology and Medicine. Tumour Biol. 17, 196-219
23. Lloyd, K. O., Yin, B. W., and Kudryashov, V. (1997) Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK-8): Identification as a mucin-type molecule. Int. J. Cancer 71, 842-850
24. Bast, R. C., Jr., Klug, T. L., St. John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., Zurawski, V. R., Jr., and Knapp, R. C. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887
25. Kenemans, P., van Kamp, G. J., Oehr, P., and Verstraeten, R. A. (1993) Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA 125 in serum. Clin. Chem. 39, 2509-2513
26. Tamakoshi, K., Kikkawa, F., Hasegawa, N., Ishikawa, H., Mizuno, K., Kawai, M., and Tomoda, Y. (1995) Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: Comparison with CA125. Gynecol. Obstet. Invest. 39, 125-129
27. Canney, P. A., Moore, M., Wilkinson, P. M., and James, R. D. (1984) Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumour marker. Br. J. Cancer 50, 765-769
28. Fritsche, H. A., and Bast, R. C. (1998) CA 125 in ovarian cancer: Advances and controversy. Clin. Chem. 44, 1379-1380
29. Zurawski, V. R., Jr., Orjaseter, H., Andersen, A., and Jellum, E. (1988) Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer. Int. J. Cancer 42, 677-680
30. Einhorn, N., Sjovall, K., Knapp, R. C., Hall, P., Scully, R. E., Bast, R. C., Jr., and Zurawski, V. R., Jr. (1992) Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Gynecol. 80, 14-18
31. Sjövall, K., Nilsson, B., and Einhorn, N. (2002) The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol. Oncol. 85, 175-178
32. van Nagell, J. R., Jr., DePriest, P. D., Reedy, M. B., Gallion, H. H., Ueland, F. R., Pavlik, E. J., and Kryscio, R. J. (2000) The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol. Oncol. 77, 350-356
33. Bailey, C. L., Ueland, F. R., Land, G. L., DePriest, P. D., Gallion, H. H., Kryscio, R. J., and van Nagell, J. R., Jr. (1998) The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol. Oncol. 69, 3-7
34. Valentin, L., Skoog, L., and Epstein, E. (2003) Frequency and type of adnexal lesions in autopsy material from postmenopausal women: Ultrasound study with histological correlation. Ultrasound Obstet. Gynecol. 22, 284-289
35. Menon, U., Talaat, A., Rosenthal, A. N., Macdonald, N. D., Jeyerajah, A. J., Skates, S. J., Sibley, K., Oram, D. H., and Jacobs, I. J. (2000) Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Br. J. Obstet. Gynaecol. 107, 165-169
36. Modesitt, S. C., Pavlik, E. J., Ueland, F. R., DePriest, P. D., Kryscio, R. J., and van Nagell, J. R. (2003) Risk of malignancy in unilocular ovarian cystic tunours less than 10 centimeters in diameter. Obstet. Gynecol. 102, 594-599
37. Ueland, F. R., DePriest, P. D., Pavlik, E. J., Kryscio, R. J., and van Nagell, J. R., Jr. (2003) Preoperative differentiation of malignant from benign ovarian tumors: The efficacy of morphology indexing and Doppler flow sonography. Gynecol. Oncol. 91, 46-50
38. Sassone, A. M., Timor-Tritsch, I. E., Artner, A., Westhoff, C., and Warren, W. B. (1991) Transvaginal sonographic characterization of ovarian disease: Evaluation of a new scoring system to predict ovarian malignancy. Obstet. Gynecol. 78, 70-76
39. Lerner, J. P., Timor-Tritsch, I. E., Federman, A., and Abramovich, G. (1994) Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am. J. Obstet. Gynecol. 170, 81-85
40. Ferrazzi, E., Zanetta, G., Dordoni, D., Berlanda, N., Mezzopane, R., Lissoni, A. A., and Lissoni, G. (1997) Transvaginal ultrasonographic characterization of ovarian masses: Comparison of five scoring systems in a multicenter study. Ultrasound Obstet. Gynecol. 10, 192-197
41. Timmerman, D., Bourne, T. H., Tailor, A., Collins, W. P., Verrelst, H., Vandenberghe, K., Vandenberghe, K., and Vergote, I. (1999) A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: The development of a new logistic regression model. Am. J. Obstet. Gynecol. 181, 57-65
42. Mol, B., Boll, D., DeKanter, M., Heintz, A. P., Sijmons, E. A., Oei, S. G., Bal, H., and Brolmann, H. A. (2001) Distinguishing the benign and malignant adnexal mass: An external validation of prognostic models. Gynecol. Oncol. 80, 162-167
43. Granberg, S., Wilkland, M., and Jansson, I. (1989) Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: Criteria to be used for ultrasound evaluation. Gynecol. Oncol. 35, 139-144
44. Holbert, T. R. (1994) Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am. J. Obstet. Gynecol. 170, 1699-1703
45. Sato, S., Yokoyama, Y., Sakamoto, T., Futagami, M., and Saito, Y. (2000) Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 89, 582-588
46. Cohen, L. S., Escobar, P. F., Scharm, C., Glimco, B., and Fishman, D. A. (2001) Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol. Oncol. 82, 40-48
47. Kurjak, A., Kupesic, S., Sparac, V., and Kosuta, D. (2000) Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet. Gynecol. 16, 365-371
48. Tailor, A., Jurkovic, D., Bourne, T. H., Collins, W. P., and Campbell, S. (1999) Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br. J. Obstet. Gynaecol. 106, 21-30
49. Clayton, R. D., Snowden, S., Weston, M. J., Mogensen, O., Eastaugh, J., and Lane, G. (1999) Neural networks in the diagnosis of malignant ovarian tumours. Br J Obstet. Gynaecol. 106, 1078-1082
50. Valentin, L., Hagen, B., Tingulstad, S., and Eik-Nes, S. (2001) Comparison of "pattern recognition" and logistic regression models for discrimination between benign and malignant pelvic masses: A prospective cross validation. Ultrasound Obstet. Gynecol. 18, 357-365
51. Folkman, J., Watson, K., Ingber, D., and Hanahan, D. (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61
52. Kurjak, A., Shalan, H., Kupesic, S., Kosuta, D., Sosic, A., Benic, S., Ilijas, M., Jukic, S., and Predanic, M. (1994) An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J. Ultrasound Med. 13, 295-301
53. Vuento, M. H., Pirhonen, J. P., Makinen, J. I., Laippala, P. J., Gronroos, M., and Salmi, T. A. (1995) Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 76, 1214-1218
54. Bourne, T. H., Campbell, S., Reynolds, K. M., Whitehead, M. I., Hampson, J., Royston, P., Crayford, T. J., and Collins, W. P. (1993) Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br. Med. J. 306, 1025-1029
55. Parkes, C. A., Smith, D., Wald, N. J., and Bourne, T. H. (1994) Feasibility study of a randomised trial of ovarian cancer screening among the general population. J. Med. Screen. 1, 209-214
56. Brown, D. L., Frates, M. C., Laing, F. C., DiSalvo, D. N., Doubilet, P. M., Benson, C. B., Waitzkin, E. D., and Muto, M. G. (1994) Ovarian masses: Can benign and malignant lesions be differentiated with color and pulsed Doppler US? Radiology 190, 333-336
57. Valentin, L. (1999) Pattern recognition of pelvic masses by gray-scale ultrasound imaging: The contribution of Doppler ultrasound. Ultrasound Obstet. Gynecol. 14, 338-347
58. Timor-Tritsch, L. E., Lerner, J. P., Monteagudo, A., and Santos, R. (1993) Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am. J. Obstet. Gynecol. 168, 909-913
59. Guerriero, S., Ajossa, S., and GianBenedetto, M. (2001) Is three-dimensional power Doppler ultrasound better than two-dimensional power Doppler? Gynecol. Oncol. 84, 352-353
60. Woolas, R. P., Conaway, M. R., Xu, F., Jacobs, I. J., Yu, Y., Daly, L., Davies, A. P., O'Briant, K., Berchuck, A., Soper, J. T., et al. (1995) Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol. 59, 111-116
61. Zhang, Z., Barnhill, S. D., Zhang, H., Xu, F., Yu, Y., Jacobs, I., Woolas, R. P., Berchuck, A., Madyastha, K. R., and Bast, R. C., Jr. (1999) Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol. Oncol. 73, 56-61
62. Crump, C., McIntosh, M. W., Urban, N., Anderson, G., and Karlan, B. Y. (2000) Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. Cancer Epidemiol. Biomarkers Prev. 9, 1107-1111
63. Jacobs, I. J., Skates, S., Davies, A. P., Woolas, R. P., Jeyerajah, A., Weidemann, P., Sibley, K., and Oram, D. H. (1996) Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: A prospective cohort study. Br. Med. J. 313, 1355-1358
64. Jacobs, I., Davies, A. P., Bridges, J., Stabile, I., Fay, T., Lower, A., Grudzinskas, J. G., and Oram, D. (1993) Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Br. Med. J. 306, 1030-1034
65. Menon, U., Talaat, A., Jeyerajah, A. R., Rosenthal, A. N., Macdonald, N. D., Skates, S. J., Sibley, K., Oram, D. H., and Jacobs, I. J. (1999) Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br. J. Cancer 80, 1644-1647
66. Jacobs, I. J., Skates, S. J., Macdonald, N., Menon, U., Rosenthal, A., Davies, A. P., Woolas, R., Jeyarajah, A. R., Sibley, K., Lowe, D. G., and Oram, D. H. (1999) Screening for ovarian cancer: A pilot randomized control trial. Lancet 353, 1207-1210
67. Skates, S. J., Pauler, D. K., and Jacobs, I. J. (2001) Screening based on the risk of ovarian cancer calculation from bayesian hierarchical change point and mixture models of longitudinal markers. J. Am. Stat. Assoc. 96, 429-439
68. Skates, S. J., Menon, U., MacDonald, N., Rosenthal, A. N., Oram, D. H., Knapp, R. C., and Jacobs, I. J. (2003) Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J. Clin. Oncol. 21 (Suppl.), 206-210
69. Grover, S., Quinn, M. A., Weidman, P., Koh, H., Robinson, H. P., Rome, R., and Cauchi, M. (1995) Screening for ovarian cancer using serum CA125 and vaginal examination: Report on 2550 females. Int. J. Gynecol. Cancer 5, 291-295
70. Adonakis, G. L., Paraskevaidis, E., Tsiga, S., Seferiadis, K., and Lolis, D. E. (1996) A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 65, 221-225
71. DePriest, P. D., Gallion, H. H., Pavlik, E. J., Kryscio, R. J., and van Nagell, J. R., Jr. (1997) Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol. Oncol. 65, 408-414
72. Hayashi, H., Yaginuma, Y., Kitamura, S., Saitou, Y., Miyamoto, T., Komori, H., Wada, K., and Ishikawa, M. (1999) Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Gynecol. Obstet. Invest. 47, 58-64
73. Tabor, A., Jensen, F. R., Bock, J. E., and Hogdall, C. K. (1994) Feasibility study of a randomised trial of ovarian cancer screening. J. Med. Screen. 1, 215-219
74. Campbell, S., Bhan, V., Royston, P., Whitehead, M. I., and Collins, W. P. (1989) Transabdominal ultrasound screening for early ovarian cancer. Br. Med. J. 299, 1363-1367
75. Millo, R., Facca, M. C., and Alberico, S. (1989) Sonographic evaluation of ovarian volume in postmenopausal women: A screening test for ovarian cancer? Clin. Exp. Obstet. Gynecol. 16, 72-78
76. Goswamy, R. K., Campbell, S., and Whitehead, M. I. (1983) Screening for ovarian cancer. Clin. Obstet. Gynaecol. 10, 621-643
77. Kurjak, A., and Kupesic, S. (1995) Transvaginal color Doppler and pelvic tumor vascularity: Lessons learned and future challenges. Ultrasound Obstet. Gynecol. 6, 145-159
78. Hasson, M. A., Fagerstrom, R. M., Kahane, D. C., Walsh, J. H., Myers, M. H., Caughman, C., et al. (2000) Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design and evolution of the data management systems in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin. Trials 21, (Suppl.) 329S-348S
79. Bourne, T. H., Campbell, S., Reynolds, K., Hampson, J., Bhatt, L., Crayford, T. J., Whitehead, M. I., and Collins, W. P. (1994) The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol. Oncol. 52, 379-385
80. Weiner, Z., Beck, D., Shteiner, M., Borovik, R., Ben-Shachar, M., Robinzon, E., and Brandes, J. M. (1993) Screening for ovarian cancer in women with breast cancer with transvaginal sonography and color flow imaging. J. Ultrasound Med. 12, 387-393
81. Muto, M. G., Cramer, D. W., Brown, D. L., Welch, W. R., Harlow, B. L., Xu, H., Brucks, J. P., Tsao, S. W., and Berkowitz, R. S. (1993) Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol. Oncol. 51, 12-20
82. Schwartz, P. E., Chambers, J. T., and Taylor, K. J. (1995) Early detection and screening for ovarian cancer. J. Cell. Biochem. 23, 233-237
83. Belinson, J. L., Okin, C., Casey, G., Ayoub, A., Klein, R., Hart, W. R., Franco, K., and Litt, R. (1995) The familial ovarian cancer registry: Progress report. Clev. Clin. J. Med. 62, 129-134
84. Menkiszak, J., Jakubowska, A., Gronwald, J., Rzepka-Gorska, I., and Lubinski, J. (1998) Hereditary ovarian cancer: Summary of 5 years of experience. (in Polish) Ginekol. Pol. 69, 283-287
85. Karlan, B. Y., Raffel, L. J., Crvenkovic, G., Smrt, C., Chen, M. D., Lopez, E., Walla, C. A., Garber, C., Cane, P., Sarti, D. A., et al. (1993) A multidisciplinary approach to the early detection of ovarian carcinoma: Rationale, protocol design, and early results. Am. J. Obstet. Gynecol. 169, 494-501
86. Karlan, B. Y., Baldwin, R. L., Lopez-Luevanos, E., Raffel, L. J., Barbuto, D., Narod, S., and Platt, L. D. (1999) Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: Implications for ovarian cancer screening. Am. J. Obstet. Gynecol. 180, 917-928
87. Dorum, A., Kristensen, G. B., Abeler, V. M., Trope, C. G., and Moller, P. (1996) Early detection of familial ovarian cancer. Eur. J. Cancer 32A, 1645-1651
88. Dorum, A., Heimdal, K., Lovslett, K., Kristensen, G., Hansen, L. J., Sandvei, R., Schiefloe, A., Hagen, B., Himmelmann, A., Jerve, F., Shetelig, K., Fjaerestad, I., Trope, C., and Moller, P. (1999) Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet. Gynecol. Scand. 78, 906-911
89. Scheuer, L., Kauff, N., Robson, M., Kelly, B., Barakat, R., Satagopan, J., Ellis, N., Hensley, M., Boyd, J., Borgen, P., Norton, L., and Offit, K. (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J. Clin. Oncol. 20, 1260-1268
90. Schorge, J. O., Muto, M. G., Welch, W. R., Bandera, C. A., Rubin, S. C., Bell, D. A., Berkowitz, R. S., and Mok, S. C. (1998) Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J. Natl. Cancer Inst. 90, 841-845
91. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., Olopade, O. I., Weber, B. L., and Prevention and Observation of Surgical End Points Study Group (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616-1622
92. Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., Ellis, N. A., Boyd, J., Borgen, P. I., Barakat, R. R., Norton, L., Castiel, M., Nafa, K., and Offit, K. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl J Med. 346, 1609-1615
93. United Kingdom Familial Ovarian Cancer Screening Study (2001) Gynaecological Oncology Unit, Institute of Cancer, Bart's and The London, Queen Mary's School of Medicine and Dentistry, London, United Kingdom
94. Cutillas, P. R., Norden, A. G., Cramer, R., Burlingame, A. L., and Unwin, R. J. (2003) Detection and analysis of urinary peptides by on-line liquid chromatography and mass spectrometry: Application to patients with renal Fanconi syndrome. Clin. Sci. 104, 483-490
95. Pang, J. X., Ginanni, N., Dongre, A. R., Hefta, S. A., and Opitek, G. J. (2002) Biomarker discovery in urine by proteomics. J. Proteome Res. 1, 161-199
96. He, Q. Y., Lau, G. K., Zhou, Y., Yuen, S. T., Lin, M. C., Kung, H. F., and Chiu, J. F. (2003) Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 3, 666-674
97. Marshall, J., Kupchak, P., Zhu, W., Yantha, J., Vrees, T., Furesz, S., Jacks, K., Smith, C., Kireeva, I., Zhang, R., Takahashi, M., Stanton, E., and Jackowski, G. (2003) Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J. Proteome Res. 2, 361-372
98. Adam, B. L., Qu, Y., Davis, J. W., Ward, M. D., Clements, M. A., Cazares, L. H., Semmes, O. J., Schellhammer, P. F., Yasui, Y., Feng, Z., and Wright, G. L., Jr. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62, 3609-3614
99. Li, J., Zhang, Z., Rosenzweig, J., Wang, Y. Y., and Chan, D. W. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48, 1296-1304
100. Jones, M. B., Krutzsch, H., Shu, H., Zhao, Y., Liotta, L. A., Kohn, E. C., Petricoin, E. F., 3rd. (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84
101. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577
102. Wulfkuhle, J. D., Liotta, L. A., and Petricoin, E. F. (2003) Proteomic applications for the early detection of cancer. Nat. Rev. Cancer 3, 267-275
103. Diamandis, E. P. (2002) Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 169-170
104. Elwood, M. (2002) Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170
105. Pearl, D. C. (2002) Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 169-170
106. Petricoin, E. F., III, Mills, G. B., Kohn, E. C., et al. (2002) Proteomic patterns in serum and identification of ovarian cancer. Lancet 360, 170-171
107. Diamandis, E. P. (2003) Proteomic patterns in biological fluids: Do they represent the future of cancer diagnostics? Clin. Chem. 49, 1272-1275
108. Sorace, J. M., and Zhan, M. (2003) A data review and reassessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4, 24